High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusionsAshraf Badros, Guido Tricot, Christopher Morris et al.|Blood|2001Cited by 188
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational studyJoshua A. Hill, Miguel‐Angel Perales, Madhav V. Dhodapkar et al.|EClinicalMedicine|2023Cited by 25
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational StudyJoshua A. Hill, Miguel‐Angel Perales, Michael J. Martens et al.|Clinical Infectious Diseases|2024Cited by 25
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101)Joshua A. Hill, Miguel‐Angel Perales, Michael J. Martens et al.|medRxiv|2024Cited by 2